AngioDynamics, Inc. (NASDAQ: ANGO) stock rose over 2.7% on 10th July, 2019 (Source: Google finance) after the company in the fourth quarter of FY 19 has reported the net income of $58.9 million compared to net income of approximately $2.1 million, a year ago. Net income was favorably impacted in the fourth quarter of FY19 on the back of the gain on the sale of the NAMIC fluid management business of $46.6 million. Adjusted EBITDAS in the fourth quarter of fiscal 2019 was $17.6 million, compared to $15.6 million in the fourth quarter of fiscal 2018. In the fourth quarter of fiscal 2019, the Company generated $25.0 million in operating cash flow and had capital expenditures of $0.9 million. As of May 31, 2019, the Company had $227.6 million in cash and cash equivalents and $132.5 million in debt, excluding the impact of deferred financing costs.
Moreover, in the fourth quarter of FY 19, the company has reported the 9% rise in the net sales to $96.3 million compared to $88.3 million a year ago. Oncology net sales were $15.3 million, which is a growth of 26.5% from $12.1 million a year ago. Strong sales of Solero, along with the recent BioSentry and RadiaDyne acquisitions, more than offset lower NanoKnife capital sales during the fourth quarter. Vascular Interventions and Therapies net sales were $56.2 million, which is an increase of 6.9%, compared to $52.6 million a year ago, as strong growth in AngioVac and our Core product line offerings was partially offset by a decline in the Venous Insufficiency business. Vascular Access net sales were $24.8 million, which is an increase of 4.9% from $23.7 million a year ago, due to higher sales of midlines, ports and dialysis. Further, U.S. net sales in the fourth quarter of fiscal 2019 were $73.4 million, a growth of 4.4% from $70.3 million a year ago, and International net sales were $22.9 million, a growth of 27% from $18 million a year ago. Gross margin for the fourth quarter of fiscal 2019 was 53.6%, approximately flat compared to the year ago quarter due to improvements in net productivity and higher volume were offset by negative impacts of price and product mix.
For the fiscal year 2020, the company expects the net sales to be in the range of $280 to $286 million and adjusted earnings per share is expected to be in the range of $0.25 to $0.30. The Company expects gross margin to be in the range of 58% to 59%.